Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Exercise Performance

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions
Precapillary Pulmonary HypertensionInterstitial Lung Disease
Interventions
BEHAVIORAL

Moderate altitude sojourn

Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days

BEHAVIORAL

Low altitude sojourn

Low altitude baseline evaluations will be performed during a stay at Zurich (490)

DRUG

Oxygen

Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m

DRUG

Sham oxygen (room air)

Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m

Trial Locations (1)

CH-8091

University Hospital Zurich, Pulmonary Division, Zurich

All Listed Sponsors
lead

University of Zurich

OTHER

NCT02143687 - Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Exercise Performance | Biotech Hunter | Biotech Hunter